Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Johnson & Johnson (JNJ.US) Tatoquimab is planned to be included in priority review in China for inhibiting tumor formation and growth

Johnson & Johnson (JNJ.US) Tatoquimab is planned to be included in priority review in China for inhibiting tumor formation and growth

智通财经智通财经2026/09/24 06:51
Show original
According to information from Zhitong Finance APP, on September 24, the CDE website showed that Johnson & Johnson's (JNJ.US) Talquetamab (Chinese brand name: Tuolike) is proposed to be included in the priority review process. It is intended for use in combination with pomalidomide to treat adult patients with relapsed or refractory multiple myeloma (R/R MM) who have previously received at least one line of therapy (including an anti-CD38 monoclonal antibody and lenalidomide).
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Microsoft integrates Office Suite into Copilot, turning the AI assistant from a “plugin” into an “entry point”, and the stock price rises by 3.7%

Microsoft has announced a major upgrade to Copilot: Word, Excel and PowerPoint will be directly integrated into this AI assistant. Additionally, new programming tool Code and a continuously running AI agent called Autopilot have been introduced, aiming to transform Copilot from a single AI assistant into a one-stop solution for office work, programming, and task execution.

华尔街见闻•2026/09/26 00:41